Platino Announces Proposed Acquisition
OXFORD, England and PHILADELPHIA, May 30, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers. Eighty-two (82) patients have been treated to date with NY-ESO-T; 44 under Adaptimmune's IND, and 38 under a National Cancer Institute IND (Robbins et al., CCR, 2014). The data from Adaptimmune's clinical studies in synovial sarcoma, multiple myeloma and ovarian cancer were presented at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting.
In this poster presentation, entitled: "Genetically Engineered NY-ESO-1 Specific T-Cells in HLA-A201+ Patients with Advanced Cancers," Melinda Merchant, M.D., Ph.D., Clinical Director of the Pediatric Oncology Branch of the National Cancer Institute, National Institutes of Health, in Bethesda, MD described the early clinical experience of the NY-ESO TCR therapeutic (NY-ESO-T) in 44 patients across indications.
The authors of the poster concluded:
- NY-ESO-T demonstrated robust clinical responses in solid and hematologic tumors, including a 60 percent (6/10) confirmed response rate in synovial sarcoma, and a 59 percent (13/22) response rate (Complete Response + near Complete Response, per International Myeloma Working Group guidelines) in myeloma in the context of autologous stem cell transplant. Approximately 62 percent (8/13) of responders had tumors with abnormal cytogenetics; 4/8 of these abnormalities are associated with high risk disease.
- In addition, a response was seen in an initial ovarian patient and patient's tumor markers were observed to be falling during this period of response. The response was abrogated by the use of systemic steroids to treat cytokine release syndrome. Reduction in pre-conditioning chemotherapy intensity in the subsequent four ovarian patients was associated with short T-cell persistence and lack of a meaningful antitumor effect. New studies are being conducted to identify the optimal dosage of pre-conditioning chemotherapy for NY-ESO-1 T-cell function.
- Durability of response ranged from 2 to 9 months, and from 3 months to ongoing response at 2.5 years in the sarcoma and myeloma studies respectively.
- NY-ESO-T has been generally well-tolerated with no long term side-effects detected to date. In the 44 patients treated under the Adaptimmune IND, the most common adverse events include diarrhea, pyrexia, and fatigue. Grade 3 cytokine release syndrome was observed in two patients, which was manageable with supportive care measures and resolved without sequelae.
- Importantly, NY-ESO-1 T-cells exhibited durable persistence without the requirement for IL-2 support in vivo, and cells were detectable for up to three years in peripheral blood by PCR. Additionally, the data show continued expression of the NY-ESO TCR for up to two years and continued NY-ESO-T function in a subset of patients, without accumulation of multiple exhaustion markers. NY-ESO-T memory phenotype is generated in persisting cells suggesting the programming of immunological memory for NY-ESO-T.
Dr. Rafael Amado, Adaptimmune's Chief Medical Officer, said, "These results - in particular the response rate in a solid tumor setting and the immune correlates of NY-ESO-T persistence, function, and the absence of T-cell exhaustion - represent important fundamental findings heretofore not observed in the field of T-cell receptor gene therapy for cancer. The data support the promise of our engineered T-cell platform as a means of augmenting a patient's immune system to fight cancer, and provide a rationale for the clinical development of additional TCR specificities across a spectrum of tumor types. We look forward to building on these findings to develop TCR-based therapeutics which may one day offer an important treatment option to patients with diverse solid and hematologic malignancies."
Data from the multiple myeloma and synovial sarcoma clinical studies were initially presented on April 21 at the 2015 annual meeting of the American Association for Cancer Research (AACR) in Philadelphia, PA by lead principal investigators, Aaron Rapoport, M.D., Professor of Medicine and Director of Lymphoma Gene Medicine, Marlene and Stewart Greenebaum Cancer Center (AACR abstract number 4701), and Dr. Merchant (AACR abstract number 4707).
Adaptimmune's NY-ESO TCR therapeutic candidate is a novel cancer immunotherapy that has been engineered to target and destroy cancer cells by strengthening a patient's natural T-cell response. T-cells are a type of white blood cell that play a central role in a person's immune response. Adaptimmune's goal is to harness the power of the T-cell and, through its NY-ESO TCR therapeutic candidate, significantly impact cancer treatment and clinical outcomes of patients with cancers, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer, lung cancer and esophageal cancer.
Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. Established in 2008, the company aims to utilize the body's own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity T-cell receptors (TCRs) as a means of strengthening natural patient T-cell responses. Adaptimmune's lead program is an affinity enhanced TCR therapeutic targeting the NY-ESO cancer antigen. Its NY-ESO TCR therapeutic candidate has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types. In June 2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialization of the NY-ESO TCR program in partnership with GSK. In addition, Adaptimmune has a number of proprietary programs and its next TCR therapeutic candidate, directed at MAGE A-10, is scheduled to enter the clinic in late 2015. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing eight of these through unpartnered research programs. Adaptimmune has over 100 employees and is located in Oxfordshire, UK and Philadelphia, USA. For more information:
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "believe," "may", "will," "estimate," "continue," "anticipate," "intend," "expect" and other words of similar meaning. These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials; our ability to submit an IND and successfully advance our technology platform to improve the safety and effectiveness of our existing TCR therapeutic candidates; the rate and degree of market acceptance of T-cell therapy generally and of our TCR therapeutic candidates; government regulation and approval, including, but not limited to, the expected regulatory approval timelines for TCR therapeutic candidates; and our ability to protect our proprietary technology and enforce our intellectual property rights; amongst others. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our final Prospectus filed with the Securities and Exchange Commission on May 7, 2015. We urge you to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
CONTACT: Adaptimmune Contacts
Vice President, Investor Relations
T: (215) 966-6264
Head of PR
T: +44 (0)1235 430036
Mob: +44 (0)7710 304249
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Adaptimmune LLC via GlobeNewswire
Abacus Data Systems' Fully Managed Technology Solutions Recognized With Finalist Nominations in the 2015 Legaltech News Innovation Awards
OTTAWA, ONTARIO--(Marketwired - May 30, 2015) -
OTTAWA, ONTARIO--(Marketwired - May 30, 2015) - Royal Galipeau, Member of Parliament (Ottawa-Orléans), on behalf of the Honourable Shelly Glover, Minister of Canadian Heritage and Official Languages, will make an announcement on Monday about l'Assemblée de la francophonie de l'Ontario.
NEW YORK, NY--(Marketwired - May 30, 2015) - This spring, Premier Traveler (PT) magazine garnered a first-place award from the Society of American Travel Writers (SATW), an organization dating back to 1955. The magazine and its Features Editor Janet Fo...
Chaired by FIFA President Blatter, the FIFA Executive Committee held its first meeting in its new composition today at the Home of FIFA in Zurich.
16,000 TELUS Volunteers Celebrate 10th Annual TELUS Days of Giving
16 000 bénévoles de TELUS célèbrent la 10e édition des Journées du bénévolat de TELUS
PALO ALTO, Calif.--(BUSINESS WIRE)--Today EdCast, a Silicon Valley based Knowledge Network company, announces “EdCasting” a new way for everyone to share their knowledge easily with bite-sized Insights across online and mobile. The launch of EdCasting includes 10 channels ranging from entrepreneurship, architecture, robotics, technology, and health, filled with insights from over 100 globally renowned experts and influencers. “EdCasting moves learning from the industrial age to the knowledge ag
OSHAWA, ONTARIO--(Marketwired - May 30, 2015) - Injured workers Richard Hudon and Peter Page, with the support of the Ontario Network of Injured Workers' Groups (ONIWG), have embarked on a 600 km bike ride from Ottawa to Toronto to coincide with June 1st Injured Workers Day demonstration and rally held for the past 33 years at Queen's Park in Toronto. The cyclists will pass through Oshawa on May 30 to draw attention to the current state of affairs at the Workers' Compensation Board known now as the Workplace Safety & Insurance Board (WSIB).
ORLANDO, FL--(Marketwired - May 30, 2015) - US Federal Contractor Registration assists small businesses with their government registration and comprehensive federal marketing campaigns. Their successful track record with helping thousands of businesses...
Following the extraordinary meeting of the FIFA Executive Committee, where the slots for the 2018 FIFA World Cup Russia™ and the 2022 FIFA World Cup Qatar 2022™ will be decided, a press conference took place on Saturday, 30 May 2015 in...
Following the extraordinary meeting of the FIFA Executive Committee, where the slots for the 2018 FIFA World Cup Russia™ and the 2022 FIFA World Cup Qatar 2022™ will be decided, a press conference will take place on Saturday, 30 May 20...
NAPLES, FL--(Marketwired - May 30, 2015) - The May 2015 edition of the rankings of best android app development services has been released by the independent research team at bestwebdesignagencies.com. The ratings consist of the thirty best android app...
NAPLES, FL--(Marketwired - May 30, 2015) - The May 2015 edition of the rankings of top small business loans services has been published by the independent research team at topcreditcardprocessors.com. The recommendations consist of the ten top small bu...
NAPLES, FL--(Marketwired - May 30, 2015) - --topseos.com has reported the May 2015 edition of the rankings of best link building companies. Internet marketing companies are placed through a process of analysis to benchmark and compare them to competito...
topcreditcardprocessors.com Releases May 2015 Rankings of Thirty Best Merchant Cash Advance Services
30 Top Android App Development Companies Named by bestwebdesignagencies.com for May 2015
100 Top Social Media Marketing Firms Announced by topseos.com for May 2015